Research library
Semaglutide, explained
12 guides, organized by the question you are trying to answer.
Research Guides
Approved Semaglutide and compounded preparations: compare the actual medicine
A practical document checklist for identifying what a semaglutide program supplies and how its evidence differs.
Semaglutide and cardiovascular outcomes: who was actually studied?
Separate SELECT and SOUL populations, outcome measures and the limits of broad heart-health claims.
Semaglutide and diabetic retinopathy: bring the eye history into the decision
Understand the SUSTAIN 6 signal, later exploratory analysis and the practical need for coordinated eye-care discussion.
Semaglutide and MASH: histology, fibrosis and the approval boundary
Read ESSENCE’s liver endpoints separately and match the current indication to the exact formulation and disease stage.
Semaglutide and kidney outcomes: read FLOW’s composite endpoint
Understand what FLOW measured in people with type 2 diabetes and chronic kidney disease before interpreting kidney-protection claims.
Semaglutide and bone health: biomarkers are not fracture outcomes
A small randomized bone study highlights why a history of low bone density deserves a separate conversation.
Semaglutide and knee osteoarthritis: pain relief is not cartilage regeneration
Read STEP 9’s pain and function endpoints without expanding them into an unsupported joint-repair claim.
Wegovy, Ozempic and Rybelsus: read the product before the promise
A route-specific map of semaglutide products, approved uses and the details to verify before comparing care.
Semaglutide salts: why the full ingredient name matters
Understand active-ingredient identity, excipients and the limits of a certificate of analysis.
Semaglutide in HFpEF: symptoms and walking capacity are specific outcomes
Understand the STEP-HFpEF population and distinguish patient-reported benefit from a general heart-failure or survival claim.
What a STEP trial result can:and cannot:predict
Learn to read semaglutide weight outcomes without turning an average into a personal forecast.
After Semaglutide stops: what withdrawal studies actually show
Read STEP 4 and the STEP 1 extension without turning group weight regain into a personal forecast or taper plan.
